Collects real-world safety data on vericiguat in Korean adults with heart failure
Collects safety data on vericiguat in people with reduced-pumping heart failure.
Key facts
- Who runs it
- Bayer
- Where
- Multiple Locations, South KoreaSee the site
- Trial code
- Registry title
- An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
- Status
- Recruiting
- People taking part
- 1,350 people, planned
- Started
- 30 Nov 2023
- Expected to end
- 31 Oct 2027
- Type of study
- Observational
- Treatments tested
- Vericiguat (Verquvo, BAY1021189)
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Korea with long-term heart failure and a weak heart pump who have been prescribed Verquvo (Vericiguat) by their doctor.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Long-term heart failure (NYHA class II, III or IV) with reduced left ventricular ejection fraction (< 45%) within 12 months before enrollment. Heart failure has worsened: hospital stay within 6 months, or intravenous diuretic therapy without a hospital stay within 3 months.
- Earlier treatment
- Must have been prescribed Verquvo (Vericiguat) as per the local approved label. Must not have had Verquvo (Vericiguat) before.
Main reasons for not taking part
- Contraindication under the local approved label, including known hypersensitivity to the drug or its components, and pregnancy
- Taking part in an investigational program with treatments outside routine clinical practice
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult aged 19 years or older
- Chronic HF (NYHA functional class II, III, or IV) Reduced left ventricular ejection fraction (< 45%) within 12 months before enrollment
- Worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months)
- Participants who have been prescribed Verquvo (Vericiguat) as per locally approved label and didn't receive Verquvo (Vericiguat) therapy previously
- Written informed consent from subject or legal representative; assent from subject when appropriate
Who cannot take part
- Contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy)
- Participants participating in an investigational program with interventions outside of routine clinical practice
Where in South Korea
- Many LocationsMultiple Locations, South KoreaTaking people
About the trial
What the trial wants to find out
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition in which the heart does not pump blood as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and death.
Read full original descriptionShow less
The study treatment vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). sGC helps to regulate the heart and blood circulation. Vericiguat has already been studied in previous clinical studies and is available for doctors to prescribe to people with heart failure. This study will collect important data from real-world setting in Korea. The participants of this study are people with HFrEF who will receive vericiguat as prescribed by their doctors according to the approved product information
The main purpose of this study is to learn more about how safe vericiguat is in the participants. To do this, researchers will collect data on all medical problems (also called adverse events) that the participants have during the study. Doctors keep track of all adverse events, even if they do not think they might be related to the study treatment.
Further, researchers will collect data on how well vericiguat works and treatment patterns in the participants. For this, the following information will be collected:
* occurrence of death due to heart and circulatory events * hospital stays due to heart conditions (failure) * dose levels of vericiguat and duration of treatment
The data for this study will come from medical records and visits that take place in routine practice. Participants will be treated with vericiguat and observed up to 12 months or until death or they leave the study, whatever comes first.
The group in the trial
- Korean adult participants with HFrEF
Korean heart failure participants with reduced ejection fraction (HFrEF) who are prescribed Verquvo (Vericiguat) for an approved indication by the Ministry of Food and Drug Safety (MFDS) in Korea
Treatment: Vericiguat (Verquvo, BAY1021189)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction
- Plain-language title
- Collects real-world safety data on vericiguat in Korean adults with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 July 2026